Anti monopoly law enforcement will strengthen the maintenance of fair competition in medicine and other markets

[market analysis of chinapharma.com] on January 3, the General Administration of Market Supervision issued a notice on the authorization of anti-monopoly law enforcement, aiming to strengthen and optimize the anti-monopoly function, enrich the anti-monopoly law enforcement force, effectively maintain fair market competition, and promote the construction of a unified, open and orderly market system nationwide On the same day, the General Administration of Market Supervision issued the regulations on the prohibition of monopoly agreement (Draft for comments) to solicit opinions from the public, so as to meet the needs of market supervision system reform and anti-monopoly law enforcement system reform, and accelerate the promotion of unified anti-monopoly law enforcement by market supervision departments after institutional reform In my opinion, anti-monopoly is very necessary for the pharmaceutical market Because monopoly is not conducive to fair competition in the market, it has hit the enthusiasm of enterprises to actively innovate production, and it will also bring patients with drug price increases, drug shortage and other situations, directly damage the interests of patients, and is not conducive to the development of social stability In recent years, the shortage and surge of drugs are more or less caused by monopoly, which is also a major attack on monopoly in China According to the data released by the General Administration of market supervision, as of the end of October 2018, 165 cases of monopoly agreements, 55 cases of abuse of market dominance were investigated and dealt with, with a total fine of more than 11 billion yuan In terms of the two major incidents in which the pharmaceutical industry has recently been hit by huge fines for monopoly, China will never tolerate the drug monopoly in the future Recently, the State Administration of Market Supervision issued the news that 12.43 million yuan will be punished according to law for monopolistic behavior of chlorpheniramine API enterprises The content shows that the two drug companies that monopolize each other have a dominant position in the market of Chlorphenamine API, but they are closely related and cooperate with each other, and they abuse the dominant position in the market Therefore, they violate the relevant provisions of the anti-monopoly law, which not only causes the price rise of API, damages the environment of fair competition in the market, but also affects the interests of patients In response, the State Administration of market supervision imposed administrative penalties on the two enterprises, ordered them to stop their illegal acts and confiscated 12.4314 million yuan in total In June 2018, the State Administration of Market Supervision issued a news about "three glacial acetic acid API manufacturing enterprises were punished 12.83 million yuan for monopolistic behavior" It also shows that after the anti-monopoly investigation, the three enterprises have restored the sales price of glacial acetic acid API to a competitive state and guaranteed the normal supply of the market In my opinion, drugs are commodities related to people's health, and the manufacturers of APIs in China are the original ones According to the data, of the 1500 kinds of chemical APIs in China, only one enterprise of 50 kinds of APIs has obtained the approval qualification for production, only two enterprises of 44 kinds of APIs can produce, and only three enterprises of 40 kinds of APIs can produce The monopoly behavior is easy to cause the price rise or shortage of downstream drugs Strengthening the anti-monopoly law enforcement will be conducive to maintaining the fair competition and stable development of API Market and safeguarding the legitimate rights and interests of patients 2018 is the 10th anniversary of the implementation of the anti monopoly law Looking back on the 10th anniversary, not only in the field of medicine, but also in various fields, the number of cases related to monopoly has continued to increase, which shows that China pays more and more attention to monopoly, resists and strictly deals with it With China's multi-faceted attack on monopoly, we believe that in the future, the competition in medicine and other markets will be more fair, further stimulate the enthusiasm of enterprises to create and innovate, and the society will be more stable and benefit more people.